Patients / advocates

WHO is preparing to ration the obesity drug revolution before it becomes another access disaster

CAR-T Starts Moving From Factory Medicine to In-Patient Engineering

FSHD Gets a Stronger Biological Signal

ALS Immunotherapy Moves Into the Extension Phase

Measles Deaths in England Expose the Cost of Missed Protection

Heatwaves are emerging as a cardiovascular risk factor, prompting calls for stronger climate adaptation and public health policies

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem

GIST Care Looks Beyond First-Generation KIT Control
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
